GFRα4 CAR T Cells in MTC Patients

• Status: Recruiting
• Trial end date: 2039-06-01

Summary

This is an open-label phase 1 study to assess the safety and feasibility of autologous T cells expressing a single-chain scFv targeting GFRα4 with tandem TCR/CD3ζ and 4-1BB (TCRζ/4-1BB) co-stimulatory domains (referred to as "CART-GFRa4 cells") in patients with incurable medullary thyroid cancer (MTC).

• Phase: Phase 1

Details

• Lead Sponsor: University of Pennsylvania
• Treatments: Cyclophosphamide; Fludarabine